Company intelligence / Profile preview

Ribosepharm

Germany

Ownership: Private
Development stage: Other

Overview

Ribosepharm specialized in the marketing and distribution of branded generic injectable oncology products, with a significant presence in the German hospital and private practice oncology market. The company was well established with favorable profit margins in its generic oncology products prior to its acquisition in 2007 by Hikma Pharmaceuticals.[1][5]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ribosepharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosepharm.

Explore the full profile